Cardiff Oncology, Inc.
CRDF- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001213037
In the last 90 days, Cardiff Oncology, Inc. insiders filed 2 open-market purchases and 0 sales; 104 institutions reported holding it in 13F filings for Q2 2026, worth $24.2M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Cardiff Oncology, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 67 | 58 | −9 |
| Shares | 8.93M | 7.93M | −1.00M (−11.2%) |
| Value | $19.6M | $12.2M | −$7.44M (−37.9%) |
New holders (5)
Institutions that held Cardiff Oncology, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Creative Planning | 25,575 | $39.0K | 0.00% |
| Jane Street Group, LLC | 20,461 | $32.0K | 0.00% |
| HighTower Advisors, LLC | 15,333 | $23.0K | 0.00% |
| Gladstone Institutional Advisory LLC | 14,000 | $22.0K | 0.00% |
| Trustcore Financial Services, LLC | 1 | $0 | 0.00% |
Sold out (14)
Institutions that held Cardiff Oncology, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Chartwell Investment Partners, LLC | 296,507 | $652.0K |
| Ergoteles LLC | 184,000 | $405.0K |
| XTX Topco Ltd | 55,081 | $121.0K |
| AQR Capital Management LLC | 54,580 | $120.0K |
| MYDA Advisors LLC | 30,000 | $66.0K |
| Two Sigma Investments, LP | 12,019 | $26.0K |
| Quantbot Technologies LP | 1,300 | $2.00K |
| New York State Common Retirement Fund | 326 | $1.00K |
| Citigroup Inc | 379 | $1.00K |
| Federated Hermes, Inc. | 196 | $1.00K |
| Captrust Financial Advisors | 409 | $1.00K |
| Tower Research Capital LLC (TRC) | 388 | $1.00K |
| Barclays PLC | 4 | $0 |
| Credit Suisse AG | 20 | $0 |